ADL Amdl,

TUSTIN, Calif., Sep. 19 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that Jade Pharmaceutical Inc. posted revenues of $3.095 million for the six months ended June 30, 2006, up 42.7 percent compared to revenues of $2.169 million for the same period in 2005. Jade Pharmaceutical posted revenues of $1.884 million for the three months ended June 30, 2006, up 56.9 percent compared to revenues of $1.201 million for the same three months in 2005. Jade Pharmaceutical's net income for the six months ended June 30, 2006 totaled $829,344 compared to $506,108 in the previous period in 2005, and its net income for the three months ended June 30, 2006 totaled $499,721 compared to $297,431 in the same period in 2005. The financial results are unaudited. Jade Pharmaceutical sells prescription pharmaceutical products and over- the-counter products in China including injectibles, capsules, tablets, liquids and medicated skin products through its two subsidiaries, JieZhong and YiQiao. AMDL shareholders overwhelmingly approved the acquisition of Jade Pharmaceutical and its two wholly owned subsidiaries at a shareholders' meeting on September 8th. "We are very pleased by the continuing, outstanding growth at Jade Pharmaceutical," said Gary Dreher, AMDL. "The closing of the acquisition is expected to occur on September 28, 2006. With the recent approval by the China State Food and Drug Administration of the Jade Pharmaceutical drug Ondansetron(R), which is highly effective in preventing nausea due to cancer treatments and represents a worldwide market exceeding $2 billion in annual sales, and the upcoming expected submission for approval of several other drugs by Jade Pharmaceutical in China, including a liver cancer treatment that is in the final stage of clinical trials in that nation, we believe the future for AMDL/Jade is very promising." About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 14 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright